List view / Grid view
14 March 2016 | By Victoria White
The Phase III programme will consist of two pivotal trials. Two doses of Lu AF35700 will be tested in patients with treatment resistant schizophrenia...
14 March 2016 | By Victoria White
The approval is based on a Phase I study that included 50 patients with ROS1-positive metastatic NSCLC treated with 250 mg of Pfizer's Xalkori (crizotinib) orally twice daily...
The Thermo Fisher Scientific™ global bio/pharma tour is an opportunity to collaborate and network directly with experts in technology innovation...
11 March 2016 | By Victoria White
A trial has shown that lapatinib plus trastuzumab before surgery shrinks and may even destroy tumours in women with HER2+ breast cancer within 11 days. The EPHOS B trial studied 257 women with HER2 positive breast cancer in the short gap between initial diagnosis and surgery to remove their tumours.…
11 March 2016 | By Victoria White
A Phase III study demonstrated that sarilumab was superior to adalimumab in improving signs and symptoms in patients with active RA...
10 March 2016 | By Victoria White
Teva is to support IVF-Worldwide with a research grant to improve knowledge of fertility preservation protocols for women diagnosed with cancer...
10 March 2016 | By Victoria White
EAF experts have issued a collaborative letter to over 350 European decision makers celebrating the year one progress of the Brussels Declaration on ADPKD...
10 March 2016 | By Victoria White
The ERADICATE Hp Phase III study was intended to evaluate the safety and efficacy of RHB-105 as a first-line treatment for confirmed H. pylori bacterial infection...
The post-hoc analysis confirms the predictive nature of the relationship between baseline blood eosinophil counts and efficacy outcomes in patients treated with mepolizumab...
9 March 2016 | By GlobalData
The UK Department of Health’s rejection of a petition to expand the routine administration of MenB vaccine Bexsero may lead to parents and physicians to consider purchasing the vaccine themselves...
9 March 2016 | By Victoria White
From today, people in Israel with radioactive iodine refractory differentiated thyroid cancer will have access to Eisai’s Lenvima (lenvatinib)...
9 March 2016 | By Victoria White
Aprea says the funds will be used to advance the clinical development of its lead programme APR-246, a first-in-class anticancer compound reactivating the tumour suppressor protein p53...
9 March 2016 | By Victoria White
Cresemba (isavuconazonium sulfate) is an azole antifungal indicated for patients 18 years of age and older for the treatment of invasive aspergillosis and invasive mucormycosis...
8 March 2016 | By Victoria White
Sanat Chattopadhyay, who's appointment will be made effective on 1 April 2016, will succeed Willie A. Deese...
8 March 2016 | By Victoria White
The addition of Spiriva Respimat to other asthma maintenance therapies helps improve asthma symptom control regardless of allergy subtype...
